Background: Stenotrophomonas maltophilia has emerged as an important opportunistic pathogen in debilitated hosts. Clinical management of S. maltophilia is challenging due to its intrinsic resistance to a variety of antibiotics. This study investigated the trend and prevalence of antimicrobial resistance in S. maltophilia from a nationwide surveillance study in Taiwan. Methods: S. maltophilia isolates were collected biennially between 1998 and 2008 as part of the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program from medical centers and regional hospitals throughout Taiwan. Minimal inhibitory concentrations (MIC) were determined using the Clinical and Laboratory Standards Institute reference broth microdilution method. Results: A total of 377 non-duplicate S. maltophilia isolates were collected from 38 hospitals. The majority of the isolates were from the respiratory tract (256, 67.9%), followed by blood (48, 12.7%). Overall, 376 (99.7%) isolates were susceptible to minocycline, 362 (96%) to tigecycline, 311 (82.5%) to trimethoprim/sulfamethoxazole (TMP-SMX), 300 (79.6%) to levofloxacin, 92 (24.4%) to ceftazidime, and 70 (18.6%) to ticarcillin-clavulanic acid. The MIC 50 /MIC 90 of minocycline, tigecycline, TMP-SMX, levofloxacin, ceftazidime, and ticarcillin-clavulanic acid, were 0.5/1 mg/mL, 0.25/1 mg/mL, 0.25/8 mg/mL, 1/4 mg/mL, 32/128 mg/mL, and 64/128 mg/mL, respectively. A trend of increased non-susceptibility to levofloxacin (p Z 0.014) was observed over the 10-year study period. Available online at www.sciencedirect.com j ourna l home pa ge: www.e-jmii.com
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Introduction
Stenotrophomonas maltophilia is a non-fermentative Gramnegative bacillus that could be found in almost all humid environments, including water, soil and plants. 1e3 It has emerged as an important opportunistic pathogen in debilitated hosts, including patients with cancer, chronic obstructive pulmonary disease, cystic fibrosis and prolonged mechanical ventilation. 4e7 The most common manifestations of S. maltophilia infection are pneumonia and blood-stream infections and, less frequently, wound and urinary tract infections. 8 Risk factors for S. maltophilia infection include use of indwelling devices, exposure to broad-spectrum antimicrobials, long hospital stays, chemotherapy-induced neutropenia of long duration, mucositis, and receipt of total parenteral nutrition. 5 Surveys in recent years showed an increasing isolation rate for S. maltophilia, probably due to increasing population of patients at risk. 8, 9 Infections caused by S. maltophilia are associated with high mortality rates. The crude mortality rates ranged from 18% to 69% and the attributable mortality rates ranged from 24% to 58%, especially in patients with hematological malignancies, neutropenia and intensive care unit (ICU) admission.
10e12 Fortunately, analysis of the risk factors for mortality showed that appropriate therapy was significantly protective. 12 However, S. maltophilia poses challenges to clinical management due to its high-level intrinsic resistance to a variety of antibiotics, especially b-lactams. 13 Of the antibiotics that are commonly investigated for in vitro activity against S. maltophilia, trimethoprim/sulfamethoxazole (TMP-SMX), fluoroquinolones, ticarcillin-clavulanic acid and minocycline appear to be the most active with lower minimal inhibitory concentrations (MICs).
14e17 Nevertheless, trends of increasing resistance to antimicrobials such as TMP-SMX and ticarcillin-clavulanic acid have been recently reported. 8, 18 On the other hand, tigecycline, the new broad-spectrum glycylcycline, has been found to be active in vitro against TMP-SMX-resistant S. maltophilia. 19, 20 In Taiwan, S. maltophilia has also been noted as an important nosocomial pathogen. From 1999 to 2004, an 85% increase in nosocomial bloodstream infections caused by S. maltophilia was noted at a medical center. 9 S. maltophilia was the sixth leading Gram-negative nosocomial pathogen in ICUs between 2003 and 2010 (Taiwan Nosocomial Infection Surveillance, 2010, Taiwan CDC unpublished data). However, national data on the susceptibility of S. maltophilia in Taiwan are limited. 9,21e24 The purpose of this study was to perform nationwide surveillance to investigate the trends of antimicrobial resistance in S. maltophilia in Taiwan.
Methods
Isolate collection and identification The collection process of the TSAR program has been described previously. 25 Each isolate was subcultured onto appropriate agar plates (BBL, Becton Dickinson Microbiology System, Cockeysville, MD, USA) to check for purity. The identification of each isolate was confirmed using a combination of standard conventional biochemical tests and Vitek 2 Gram-negative identification cards (bioMérieux, Maray l'Etoile, France).
Antimicrobial susceptibility testing
The MICs of seven antibiotics were determined by the reference broth microdilution method following the guidelines of the Clinical and Laboratory Standards Institute (CLSI) using freshly prepared cation-adjusted MuellerHinton broth. 26 The antibiotics tested included ceftazidime (1e128 mg/mL), chloramphenicol (8e32 mg/mL), levofloxacin (0.25e64 mg/mL), minocycline (0.5e64 mg/mL), ticarcillin-clavulanic acid (1/2e128/2 mg/mL), TMP-SMX (0.25e32 mg/mL) and tigecycline (0.12e4 mg/mL). Customdesigned 96 well panels (Sensititre, Trek diagnostics, West Sussex, UK) were used with a final inoculum of 5 Â 10 5 colony forming units /mL at 100 mL per well. For tigecycline, the criteria of 1 mg/mL for susceptibility and !2.0 mg/mL for resistance were applied based on the clinical breakpoints of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for Enterobacteriaceae.
27
CLSI interpretive criteria for S. maltophilia were used for other agents. Quality control was performed on each day of testing with Escherichia coli ATCC 25922 and Psuedomonas aeruginosa ATCC 27853.
Statistical analysis
Susceptibility interpretation analysis was made using Whonet software (http://www.who.int/drugresistance/ whonetsoftware/en/). Univariate analysis was performed using SPSS statistics 17.0 software (IBM Corporation, Somers, NY). Significance of differences in frequencies and proportions were tested by c 2 test.
Results
During the 10-year study period, a total of 377 non-duplicate S. maltophilia isolates were collected. Table 2 . Overall, 376 (99.7%) isolates were susceptible to minocycline, 311 (82.5%) to TMP-SMX, 300 (79.6%) to levofloxacin, 92 (24.4%) to ceftazidime, and 70 (18.6%) to ticarcillin-clavulanic acid based on the CLSI interpretive criteria. The MIC 50 /MIC 90 of minocycline, TMP-SMX, levofloxacin, ceftazidime, and ticarcillin-clavulanic acid were 0.5/1 mg/mL, 0.25/8 mg/mL, 1/4 mg/mL, 32/ 128 mg/mL, and 64/128 mg/mL, respectively. The MIC 50 and MIC 90 of tigecycline were 0.25 mg/mL and 1 mg/mL, respectively, and 362 (96%) isolates were susceptible (MIC 1 mg/mL). For better comparison of their in vitro activities, the MIC distribution of ceftazidime, levofloxacin, minocycline, TMP-SMX, ticarcillin-clavulanic acid and tigecycline is shown in Fig. 1 . The susceptibility rates of S. maltophilia isolates from different patient locations (ICU vs. non-ICU inpatients vs. outpatients), and specimen types (blood vs. respiratory) were compared (Table 3 ). Except minocycline, to which nearly all isolates were susceptible, isolates from ICUs had higher rates of nonsusceptibility than isolates from non-ICU and outpatients, but the differences were not statistically significant (p > 0.05 for all agents). Isolates from the respiratory tract were less susceptible than those from blood, especially to ceftazidime (45.8% vs. 18.0%, p < 0.01) and chloramphenicol (83.3% vs. 68.4%, p Z 0.039). Compared to TMP/SMX-susceptible isolates, TMP/SMXresistant isolates were less susceptible, especially to chloramphenicol (51.5% vs. 72.3%, p Z 0.001) and levofloxacin (54.5% vs. 84.9%, p < 0.001; Table 3 ).
While the susceptibility of S. maltophilia to ceftazidime, minocycline, ticarcillin-clavulanic acid and TMP-SMX did not change significantly over the 10-year study period, a trend of decreased susceptibility to levofloxacin (83.7% in 1998 to 65.6% in 2008, p Z 0.014) was observed (Fig. 2) . Among all 377 isolates, there was only one isolate with multidrug resistance to ceftazidime, chloramphenicol, levofloxacin, TMP-SMX and ticarcillinclavulanic acid.
Discussion
The present study evaluated the susceptibility of clinical S. maltophilia isolates collected over a 10-year period in Taiwan. We found that the activities of TMP-SMX and minocycline remained similarly high over the years. However, the activity of levofloxacin against S. maltophilia has declined. In addition, TMP/SMX-resistant isolates were Figure 1 . Minimal inhibitory concentration distribution of ceftazidime, levofloxacin, minocycline, ticarcillin-clavulanic acid, tigecycline, and trimethoprim/sulfamethoxazole against 377 isolates of S. maltophilia. TMP/SMX Z trimethoprim/ sulfamethoxazole. significantly less susceptible than TMP/SMX-susceptible isolates to levofloxacin.
In a recent study by Farrell et al, 17 who evaluated susceptibilities of 1586 S. maltophilia clinical isolates collected worldwide between 2003 and 2008, rates of susceptibility to ceftazidime, levofloxacin, ticarcillinclavulanic acid, and TMP-SMX were 44.8%, 83.4%, 39.1%, and 96.0%, respectively. In comparison, S. maltophilia isolates in our study showed significantly lower susceptibility to ceftazidime (24.4% vs. 44.8%, p < 0.01), ticarcillinclavulanic acid (18.6% vs. 39.1%, p < 0.01) and TMP-SMX (82.5% vs. 96.0%, p < 0.01), while susceptibility to levofloxacin was similar between the two studies (79.6% vs. 83.4%, p Z 0.082). Of note, the low susceptibility to ticarcillin-clavulanic acid was due in part to the large proportions of isolates in the intermediate category (55.9% vs. 36.7%) in both studies.
The differences in susceptibility rates between the two studies may be in part due to differences in specimen source. In the study by Farrell et al, 17 over half of the isolates were from blood (51%), while respiratory isolates comprised smaller proportion (37%), and no comparison was made on susceptibility from the two specimen groups. In contrast, the majority of our isolates were from the respiratory tract (67.9%). Although there were fewer blood isolates (48, 12.7%) in our study, it is worth noting that blood isolates were more susceptible to all the agents than respiratory isolates, especially ceftazidime (45.8% vs. 18%). In addition, isolates from the Asia-Pacific region in the study of Farrell et al had the lowest rates of susceptibility to ceftazidime (32.6%), levofloxacin (78.0%), ticarcillinclavulanic acid (27.0%), and TMP-SMX (90.8%) compared to isolates from North America, Europe, and Latin America. Thus, S. maltophilia isolates from the Asia-Pacific region appeared to be less susceptible to these agents.
We also found a trend of decreased susceptibility to levofloxacin over the 10-year period. Although rapid emergence of resistance against fluoroquinolones has been observed in vitro and in vivo for S. maltophilia, 8, 28 this is, to our knowledge, the first study to investigate levofloxacin resistance over a long period of time. One possible explanation for this finding is that resistant mutants may have emerged following exposure to fluoroquinolones. 28, 29 Increased fluoroquinolone use has been associated with decreasing susceptibility to fluoroquinolones in many Gramnegative pathogens. 30 The present study found tigecycline to have potent in vitro activity against S. maltophilia isolates in Taiwan, with MIC 50 /MIC 90 of 0.25/1 mg/mL, which were one dilution lower than those reported by Farrell et al, (0.5/2 mg/mL).
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In another study which evaluated the antimicrobial activities against isolates collected from ICUs worldwide, tigecycline also exhibited potent in vitro activity against S. maltophilia. 19 Further studies are needed to determine their clinical efficacy.
There were some limitations to this study. First, although the isolates we tested were from various clinical specimens, there was a predominance of respiratory specimens. Since isolates from the respiratory tract showed higher resistance rates than those from blood, including to ceftazidime and chloramphenicol, further studies are needed to confirm the higher susceptibilities of bloodstream isolates. Second, due to limited clinical information, we could not determine if all S. maltophilia isolates caused infections in the patients from whom the isolates were recovered.
In conclusion, the results of this study suggest that minocycline and TMP/SMX remain the two most potent antibiotics against S. maltophilia in Taiwan, although more clinical trials or observational studies are needed to confirm their efficacy. Since S. maltophilia demonstrated a decreasing trend of susceptibility to levofloxacin, and since TMP/SMXresistant isolates also had lower levofloxacin susceptibility, use of higher doses of fluoroquinolone or in combination with other antibiotics with better in vitro activity should be considered if fluoroquinolones are to be used. Finally, this study indicated that continued surveillance of antimicrobial resistance in S. maltophilia to fluoroquinolones and other antibiotics is warranted.
